Floatz logo

Sorafenib

Acute Myeloid Leukemia, FLT3 Internal Tandem Duplication

The First Affiliated Hospital of Soochow UniversitySmall moleculePhase 3Active
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
53/ 100
Competitive Position
89/ 100

Competitive context

9 Active assets in the Acute Myeloid Leukemia, FLT3 Internal Tandem Duplication cohort.

Asset / SponsorPhaseRating
Gilteritinib
The First Affiliated Hospital of Soochow University
Phase 3BB
Azacitidine
French Innovative Leukemia Organisation
Phase 2BB
Cytarabine
First Affiliated Hospital of Zhejiang University
Phase 3BB
Quizartinib
M.D. Anderson Cancer Center
Phase 2BB
Daunomycin
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 3BB

View all 21 →

Same molecule, other indications

Sorafenib is also rated in:

renal cell carcinomaDormant
BBB
Indicative · Phase 4
79 / 100
View asset →
portal vein thrombosisDormant
BBB
Indicative · Phase 4
74 / 100
View asset →
adult hepatocellular carcinomaDormant
BBB
Indicative · Phase 3
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →